|
Home Ā» Briefs Ā» Tyco Healthcare Group LP et al v. Pharmaceutical Holdings Corp., et al

Services

Econ One’s expert economists have experience across a wide variety of services including antitrust, class certification, damages, financial markets and securities, intellectual property, international arbitration, labor and employment, and valuation and financial analysis.

Resources

Econ One’s resources including blogs, cases, news, and more provide a collection of materials from Econ One’s experts.

Cases and Engagements
Get an Inside look at Economics with the experts.
Managing Director
Education

Ph.D. in Economics, University of California, Los Angeles

M.A. in Economics, University of California, Los Angeles

B.S. in Economics, Santa Clara University

Econ One, President, 1997 ā€“ Present

Founded Econ One, 1997

Micronomics, Inc., President and CEO, 1994 ā€“ 1997

Micronomics, Inc., Executive Vice President, 1988 ā€“ 1997

Cofounded Micronomics, Inc., 1988

National Economic Research Associates, Inc. (Last position was Senior Vice President and member of the Board of Directors) 1980 ā€“ 1988

U.S. District Court

U.S. Bankruptcy Court

State Court

Federal Energy Regulatory Commission

Various state tax and regulatory commissions

Private arbitration

International Arbitration

Share this Article
September 25, 2015

Tyco Healthcare Group LP et al v. Pharmaceutical Holdings Corp., et al

Econ One was retained by counsel for Mutual in the case Tyco Healthcare Group LP et al v. Pharmaceutical Holdings Corp., et al. In their counterclaims, plaintiffs (Mutual) claimed that defendants (Tyco) delayed the entry of Mutualā€™s generic to the brand name drug Restoril 7.5 mg.

Econ One expert Jeffrey Leitzinger was asked to define the market relevant to the analysis of the antitrust claims in this matter.Ā  He also was asked to analyze whether the delay in Mutualā€™s entry as a competitor enhanced (i.e., created, increased, or maintained) monopoly power on the part of Tyco within the relevant market.Ā  Finally, he was asked to calculate Mutualā€™s lost profits. Dr. Leitzinger submitted an expert report and provided deposition testimony.

Industries: Pharmaceutical
Latest Related Resources and Insights